Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0045-1802565
Original Article

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study

Dinesh Chandra Doval
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India
,
Tanveer Maksud
2   Department of Medical Oncology, Unique Hospital Multispecialty & Research Institute, Surat, Gujarat, India
,
Rajnish Nagarkar
3   Department of Surgical Oncology, HCG Manavata Cancer Centre, HCG Manavata Cancer Centre, Nashik, Maharashtra, India
,
Satheesh Chiradoni Thunagappa
4   Department of Medical Oncology, HCG Cancer Centre, Bengaluru, Karnataka, India
,
Rakesh Taran
5   Department of Medical Oncology, SRJ-CBCC Cancer Hospital, Indore, Madhya Pradesh, India
,
Saurabh Prasad
6   Department of Medical Oncology, Kingsway Hospital, Nagpur, Maharashtra, India
,
Anoop T. Manoharan 
7   Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Minish Jain
8   Department of Medical Oncology, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India
,
Dhruv Mehta
9   Department of Medical Oncology, Nirmal Hospital Pvt. Ltd., Surat, Gujarat, India
,
Prabrajya Narayan Mohapatra
10   Department of Medical Oncology, Apollo Gleneagles Hospital, Salt Lake, Kolkata, West Bengal, India
,
Sachin Gupta
11   Department of Medical Oncology, Max Super Specialty Hospital, Chandigarh, India
,
Kritarth Naman Singh
12   Clinical Research Physician (Oncology), Eli Lilly and Company (India) Pvt. Ltd., Gurgaon, Haryana, India
,
Aarohan Pruthi
13   Senior Director - Medical (Oncology), Eli Lilly and Company (NAPAC), Sydney, Australia
,
Rohit Arora
14   Senior Director - Medical Development, Eli Lilly Services India Private Limited, Bangalore, Karnataka, India
› Author Affiliations Trial Registration Numbers Clinicaltrials.gov - NCT04707196 and Clinical Trials Registry - India (CTRI) - CTRI/2020/12/030021.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Global phase III trials demonstrated efficacy of abemaciclib in patients with HR +/HER2– metastatic breast cancer (BC) as a first-line therapy in combination with a nonsteroidal aromatase inhibitor (MONARCH-3) or with fulvestrant following progression after endocrine therapy (ET) (MONARCH-2). However, there is limited data on safety and tolerability of abemaciclib plus ET in the metastatic BC setting among Indian patients, which the present study aims to address.

Materials and Methods An open-label, single-arm, phase IV study was conducted across 16 centers in India to assess the safety and tolerability of abemaciclib in patients with HR +/HER2– locally advanced or metastatic BC. Patients were assigned to either cohort A, ET-naive patients (abemaciclib + anastrozole/letrozole) or cohort B, patients progressing after previous ET (abemaciclib + fulvestrant), targeting the same patient population as the global phase III MONARCH-3 and MONARCH-2 trials, respectively. Primary endpoints were all-cause adverse events (AEs) including serious AEs (SAEs).

Statistical Analysis The statistical analysis was conducted using SAS Version 9.4.

Results Two hundred patients were enrolled, with a mean age of 54 years, most (77.0%) were aged ≤ 65 years. The median duration of exposure was similar in both cohorts (cohort A vs. B: 24.3 vs. 24.4 weeks). Overall, 75.5 % of patients reported all-cause AEs, of which 38.5% of the patients reported AEs Common Terminology Criteria for Adverse Events grade 3 and above. The most common grade 3 and above all-cause AEs for abemaciclib were neutropenia (19.0%), followed by anemia (14.0%) and diarrhea (5.5%). Fourteen (7.0%) patients encountered SAEs, including infections (2.0%) and gastrointestinal disorders (1.5%). Most of the patients continued their treatments with appropriate dose reductions (25.5%) and dose omissions (40.5%), and only 2.5% of patients discontinued study treatment due to treatment-related AEs.

Conclusion Abemaciclib in combination with ET was found to have an acceptable tolerability in Indian patients with HR +/HER2– advanced and metastatic BC, consistent with the established safety data as reported in the pivotal global studies. No new clinical safety concerns were identified, with most of the reported AEs and SAEs managed by dose adjustments.

Keywords

breast cancer - endocrine therapy - CDK4/6 inhibitors - abemaciclib - advanced breast cancer - India

Authors' Contributions

All authors contributed significantly to the study. D.C.D., T.M., R.N., S.C.T., R.T., S.P., A.T. M., M.J., D.M., P.N.M. and S.G. were involved in the acquisition and interpretation of data, critical revision of the manuscript, and approval of the final version of the manuscript. S.G. also contributed to the acquisition and interpretation of data, critical revision of the manuscript, and approval of the final version. K.N.S. played a key role in interpreting the results, preparing the manuscript draft, and approving the final version. A.P. and R.A. contributed to the conception and design of the study, interpretation of the data, critical revision of the manuscript, and approval of the final version. All authors have approved the final manuscript.


Ethical Approval and Statement of Conforming to the Declaration of Helsinki

The study's protocol (I3Y-IN-JPEC) received approval from the ethics committees of all the participating centers. It adhered to ethical principles from international guidelines such as the Declaration of Helsinki, the Council for International Organizations of Medical Sciences (CIOMS), and the International Conference on Harmonisation's (ICH) Good Clinical Practice (GCP) guidelines, in addition to relevant laws and regulations (Clinicaltrials.gov - NCT04707196; Clinical Trials Registry - India (CTRI) - CTRI/2020/12/030021). All patients provided written informed consent before enrollment.


Supplementary Material



Publication History

Received: 16 September 2024

Accepted: 07 January 2025

Article published online:
31 January 2025

© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 WHO. Breast cancer: Globocan 2022: World Health Organization: International Agency for research on Cancer. Accessed March 13, 2024 at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf
  • 2 WHO. India: Globocan 2022. Accessed March 13, 2024 at: https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf
  • 3 Mehrotra R, Yadav K. Breast cancer in India: present scenario and the challenges ahead. World J Clin Oncol 2022; 13 (03) 209-218
    CrossrefPubMedSearch in Google Scholar
  • 4 Sathishkumar K, Sankarapillai J, Mathew A. et al. Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme. Cancer 2024; 130 (10) 1816-1825
    CrossrefPubMedSearch in Google Scholar
  • 5 Gogia A, Deo SVS, Sharma D. et al. Clinicopathologic characteristics and treatment outcomes of patients with up-front metastatic breast cancer: single-center experience in India. J Glob Oncol 2019; 5: 1-9
    CrossrefPubMedSearch in Google Scholar
  • 6 Cardoso F, Senkus E, Costa A. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29 (08) 1634-1657
    CrossrefPubMedSearch in Google Scholar
  • 7 Flaum LE, Gradishar WJ. Advances in endocrine therapy for postmenopausal metastatic breast cancer. Cancer Treat Res 2018; 173: 141-154
    CrossrefPubMedSearch in Google Scholar
  • 8 Meegdes M, Geurts SME, Erdkamp FLG. et al. Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry. Lancet Reg Health Eur 2023; 26: 100573
    CrossrefPubMedSearch in Google Scholar
  • 9 Gennari A, André F, Barrios CH. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021; 32 (12) 1475-1495
    CrossrefPubMedSearch in Google Scholar
  • 10 Guidelines®) NCCN Clinical Practice Guidelines in Oncology (NCCN). Breast Cancer 2023. Accessed January 16, 2025 at: www.nccn.org/patients
  • 11 Burstein HJ, Somerfield MR, Barton DL. et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline update. J Clin Oncol 2021; 39 (35) 3959-3977
    CrossrefPubMedSearch in Google Scholar
  • 12 Tolaney SM, Beeram M, Beck JT. et al. Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a phase 1b study. Front Oncol 2022; 11: 810023
    CrossrefPubMedSearch in Google Scholar
  • 13 FDA. FDA approves abemaciclib for HR-positive, HER2-negative breast cancer 2017. Accessed March 20, 2024 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-hr-positive-her2-negative-breast-cancer
  • 14 Patnaik A, Rosen LS, Tolaney SM. et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 2016; 6 (07) 740-753
    CrossrefPubMedSearch in Google Scholar
  • 15 Dickler MN, Tolaney SM, Rugo HS. et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer. Clin Cancer Res 2017; 23 (17) 5218-5224
    CrossrefPubMedSearch in Google Scholar
  • 16 Sledge Jr GW, Toi M, Neven P. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35 (25) 2875-2884
    CrossrefPubMedSearch in Google Scholar
  • 17 Torres-Guzmán R, Calsina B, Hermoso A. et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget 2017; 8 (41) 69493-69507
    CrossrefPubMedSearch in Google Scholar
  • 18 Gelbert LM, Cai S, Lin X. et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014; 32 (05) 825-837
    CrossrefPubMedSearch in Google Scholar
  • 19 Sledge Jr GW, Toi M, Neven P. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 2020; 6 (01) 116-124
    CrossrefPubMedSearch in Google Scholar
  • 20 Goetz MP, Toi M, Huober J. et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 2024
    Search in Google Scholar
  • 21 Johnston S, Martin M, Di Leo A. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019; 5: 5
    CrossrefPubMedSearch in Google Scholar
  • 22 Zhang QY, Sun T, Yin YM. et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol 2020; 12: 17 58835920963925
    CrossrefPubMedSearch in Google Scholar
  • 23 CDSCO. List of new drugs approved in the year 2019 till date 2019. Accessed March 13, 2024 at: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalNewDrugs/ndedec13appro.pdf
  • 24 Takahashi M, Tokunaga E, Mori J. et al. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer 2022; 29 (01) 174-184
    CrossrefPubMedSearch in Google Scholar
  • 25 Lee KWC, Lord S, Finn RS. et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat 2019; 174 (01) 271-278
    CrossrefPubMedSearch in Google Scholar
  • 26 Goetz MP, Toi M, Campone M. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017; 35 (32) 3638-3646
    CrossrefPubMedSearch in Google Scholar
  • 27 Rugo HS, Huober J, García-Sáenz JA. et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26 (01) e53-e65
    CrossrefPubMedSearch in Google Scholar
  • 28 Parikh PM, Amish V, Rajan Y. et al. Consensus guidelines for the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in the management of hormone receptor positive (HR+ ve), Her2− ve early breast cancer (EBC). South Asian J Cancer 2024
    Search in Google Scholar
  • 29 Kaur M. Dietary intake, prevalence, and the effect of anemia on various morphophysiological variables of postmenopausal women of North India. J Midlife Health 2018; 9 (02) 72-78
    PubMedSearch in Google Scholar